

Minoru Fujimoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5454201/publications.pdf>

Version: 2024-02-01

96
papers

5,789
citations

76294

40
h-index

79644

73
g-index

97
all docs

97
docs citations

97
times ranked

7881
citing authors

#	ARTICLE	IF	CITATIONS
1	SOCS-1 Participates in Negative Regulation of LPS Responses. <i>Immunity</i> , 2002, 17, 677-687.	6.6	583
2	IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 9041-9046.	3.3	308
3	Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. <i>Arthritis and Rheumatism</i> , 2008, 58, 3710-3719.	6.7	211
4	Regulation of cytokine signaling by SOCS family molecules. <i>Trends in Immunology</i> , 2003, 24, 659-666.	2.9	202
5	iTRAQ-based proteomic identification of leucine-rich α -2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 770-774.	0.5	179
6	SOCS-1/SSI-1-Deficient NKT Cells Participate in Severe Hepatitis through Dysregulated Cross-Talk Inhibition of IFN- γ and IL-4 Signaling In Vivo. <i>Immunity</i> , 2001, 14, 535-545.	6.6	176
7	Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2169-2179.	0.9	161
8	Signal Transducer and Activator of Transcription (Stat)-Induced Stat Inhibitor 1 (Ssi-1)/Suppressor of Cytokine Signaling 1 (Socs1) Inhibits Insulin Signal Transduction Pathway through Modulating Insulin Receptor Substrate 1 (Irs-1) Phosphorylation. <i>Journal of Experimental Medicine</i> , 2001, 193, 263-270.	4.2	138
9	The Influence of Excessive IL-6 Production In Vivo on the Development and Function of Foxp3+ Regulatory T Cells. <i>Journal of Immunology</i> , 2011, 186, 32-40.	0.4	133
10	Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation. <i>Journal of Controlled Release</i> , 2010, 143, 311-317.	4.8	131
11	Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 219-230.	1.5	123
12	Flavonoids such as Luteolin, Fisetin and Apigenin Are Inhibitors of Interleukin-4 and Interleukin-13 Production by Activated Human Basophils. <i>International Archives of Allergy and Immunology</i> , 2004, 134, 135-140.	0.9	118
13	Blockade of Interleukin-6 Receptor Alleviates Disease in Mouse Model of Scleroderma. <i>American Journal of Pathology</i> , 2012, 180, 165-176.	1.9	115
14	Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. <i>Trends in Biochemical Sciences</i> , 1999, 24, 394-398.	3.7	111
15	Proteomics-based identification of β -enolase as a tumor antigen in non-small lung cancer. <i>Cancer Science</i> , 2007, 98, 1234-1240.	1.7	102
16	Periostin, a matricellular protein, accelerates cutaneous wound repair by activating dermal fibroblasts. <i>Experimental Dermatology</i> , 2012, 21, 331-336.	1.4	101
17	Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 84-91.	0.6	100
18	SOCS1, a Negative Regulator of Cytokine Signals and TLR Responses, in Human Liver Diseases. <i>Gastroenterology Research and Practice</i> , 2010, 2010, 1-7.	0.7	95

#	ARTICLE	IF	CITATIONS
19	IL-18 gene polymorphisms affect IL-18 production capability by monocytes. <i>Biochemical and Biophysical Research Communications</i> , 2006, 342, 1413-1416.	1.0	92
20	Periostin Facilitates Skin Sclerosis via PI3K/Akt Dependent Mechanism in a Mouse Model of Scleroderma. <i>PLoS ONE</i> , 2012, 7, e41994.	1.1	89
21	Negative Regulation of Cytokine and TLR Signalings by SOCS and Others. <i>Advances in Immunology</i> , 2005, 87, 61-122.	1.1	87
22	IFN Regulatory Factor-1-Mediated Transcriptional Activation of Mouse STAT-Induced STAT Inhibitor-1 Gene Promoter by IFN- β . <i>Journal of Immunology</i> , 2000, 164, 5833-5843.	0.4	83
23	Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. <i>Experimental Eye Research</i> , 2010, 91, 162-170.	1.2	82
24	Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice. <i>International Immunology</i> , 2008, 20, 753-762.	1.8	76
25	Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2016, 115, 66-75.	2.9	76
26	Defective Thymocyte Development and Perturbed Homeostasis of T cells in STAT-Induced STAT Inhibitor-1/Suppressors of Cytokine Signaling-1 Transgenic Mice. <i>Journal of Immunology</i> , 2000, 165, 1799-1806.	0.4	73
27	Luteolin, a flavonoid, inhibits AP-1 activation by basophils. <i>Biochemical and Biophysical Research Communications</i> , 2006, 340, 1-7.	1.0	72
28	IL-6-mediated Th17 differentiation through ROR γ t is essential for the initiation of experimental autoimmune myocarditis. <i>Cardiovascular Research</i> , 2011, 91, 640-648.	1.8	72
29	Brief Report: Leucine-Rich Glycoprotein as a Potential Biomarker for Joint Inflammation During Anti-Interleukin-6 Biologic Therapy in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2056-2060.	2.9	71
30	Blockade of Interleukin-6 Signaling Suppresses Not Only Th17 but Also Interphotoreceptor Retinoid Binding Protein-Specific Th1 by Promoting Regulatory T Cells in Experimental Autoimmune Uveoretinitis. , 2011, 52, 3264.		70
31	Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. <i>British Journal of Haematology</i> , 2004, 126, 726-735.	1.2	68
32	A regulatory role for suppressor of cytokine signaling-1 in Th polarization in vivo. <i>International Immunology</i> , 2002, 14, 1343-1350.	1.8	66
33	Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases. <i>International Immunology</i> , 2004, 16, 303-314.	1.8	64
34	Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. <i>International Journal of Cancer</i> , 2009, 125, 2316-2322.	2.3	59
35	Antiproliferative effect of SOCS-1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells. <i>International Journal of Cancer</i> , 2012, 131, 1287-1296.	2.3	57
36	Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. <i>International Journal of Cancer</i> , 2013, 132, 472-484.	2.3	56

#	ARTICLE	IF	CITATIONS
37	Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer. <i>International Journal of Cancer</i> , 2018, 142, 1056-1066.	2.3	52
38	Periostin accelerates human malignant melanoma progression by modifying the melanoma microenvironment. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 630-639.	1.5	50
39	Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: Evaluation in comparison with mesothelin. <i>Lung Cancer</i> , 2008, 62, 45-54.	0.9	46
40	Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 24741-24752.	0.8	46
41	Leucine-rich alpha 2 glycoprotein promotes Th17 differentiation and collagen-induced arthritis in mice through enhancement of TGF- β -Smad2 signaling in naive helper T cells. <i>Arthritis Research and Therapy</i> , 2017, 19, 137.	1.6	45
42	Sputum Leucine-Rich Alpha-2 Glycoprotein as a Marker of Airway Inflammation in Asthma. <i>PLoS ONE</i> , 2016, 11, e0162672.	1.1	44
43	LRG is a novel inflammatory marker clinically useful for the evaluation of disease activity in rheumatoid arthritis and inflammatory bowel disease. <i>Immunological Medicine</i> , 2018, 41, 62-67.	1.4	43
44	Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma. <i>International Journal of Cancer</i> , 2011, 129, 993-1005.	2.3	42
45	SOCS1 Gene Therapy Improves Radiosensitivity and Enhances Irradiation-Induced DNA Damage in Esophageal Squamous Cell Carcinoma. <i>Cancer Research</i> , 2017, 77, 6975-6986.	0.4	39
46	Leucine-rich α -2 glycoprotein promotes lung fibrosis by modulating TGF- β signaling in fibroblasts. <i>Physiological Reports</i> , 2017, 5, e13556.	0.7	38
47	NQO1 inhibits the TLR-dependent production of selective cytokines by promoting β -B-1 degradation. <i>Journal of Experimental Medicine</i> , 2018, 215, 2197-2209.	4.2	37
48	TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naive and imatinib-resistant gastrointestinal stromal tumours. <i>British Journal of Cancer</i> , 2020, 122, 658-667.	2.9	37
49	Myeloid cell-derived LRG attenuates adverse cardiac remodelling after myocardial infarction. <i>Cardiovascular Research</i> , 2016, 109, 272-282.	1.8	36
50	New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis. <i>International Journal of Cancer</i> , 2013, 133, n/a-n/a.	2.3	35
51	Histamine Contributes to Tissue Remodeling via Periostin Expression. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2105-2113.	0.3	34
52	Cell surface localization of importin β 1/KPNA2 affects cancer cell proliferation by regulating FGF1 signalling. <i>Scientific Reports</i> , 2016, 6, 21410.	1.6	33
53	Leucine-rich α -2-glycoprotein promotes TGF β 1-mediated growth suppression in the Lewis lung carcinoma cell lines. <i>Oncotarget</i> , 2015, 6, 11009-11022.	0.8	31
54	Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice. <i>International Journal of Cancer</i> , 2017, 140, 2608-2621.	2.3	31

#	ARTICLE	IF	CITATIONS
55	LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake. <i>Cancer Research</i> , 2018, 78, 516-527.	0.4	31
56	Luteolin, a Flavonoid, Inhibits CD40 Ligand Expression by Activated Human Basophils. <i>International Archives of Allergy and Immunology</i> , 2006, 140, 150-156.	0.9	30
57	Leucine rich α 2 glycoprotein is a potential urinary biomarker for renal tubular injury. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 1045-1051.	1.0	29
58	Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling α 1 in non-small cell lung cancer cells. <i>Cancer Science</i> , 2013, 104, 1483-1491.	1.7	28
59	Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A. <i>International Journal of Cancer</i> , 2014, 134, 1796-1809.	2.3	28
60	Salt-inducible kinase 3 deficiency exacerbates lipopolysaccharide-induced endotoxin shock accompanied by increased levels of pro-inflammatory molecules in mice. <i>Immunology</i> , 2015, 145, 268-278.	2.0	28
61	Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. <i>British Journal of Cancer</i> , 2020, 122, 1333-1341.	2.9	27
62	SOCS α 1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma. <i>International Journal of Cancer</i> , 2013, 132, 459-471.	2.3	25
63	Leucine-rich α 2 glycoprotein is an innovative biomarker for psoriasis. <i>Journal of Dermatological Science</i> , 2017, 86, 170-174.	1.0	24
64	Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner. <i>Oncotarget</i> , 2014, 5, 7776-7787.	0.8	24
65	SOCS-2 interferes with myotube formation and potentiates osteoblast differentiation through upregulation of JunB in C2C12 cells. <i>Journal of Cellular Physiology</i> , 2006, 207, 428-436.	2.0	22
66	Reprint of: Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation. <i>Journal of Controlled Release</i> , 2011, 149, 58-64.	4.8	22
67	Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas. <i>British Journal of Cancer</i> , 2016, 114, 554-561.	2.9	22
68	Gene therapy with SOCS1 for gastric cancer induces G2/M arrest and has an antitumour effect on peritoneal carcinomatosis. <i>British Journal of Cancer</i> , 2015, 113, 433-442.	2.9	21
69	Epithelial-mesenchymal transition via transforming growth factor beta in pancreatic cancer is potentiated by the inflammatory glycoprotein leucine α 2 glycoprotein. <i>Cancer Science</i> , 2019, 110, 985-996.	1.7	20
70	Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 491-502.	0.9	19
71	Suppressor of cytokine signaling 1 suppresses muscle differentiation through modulation of IGF-I receptor signal transduction. <i>Biochemical and Biophysical Research Communications</i> , 2005, 328, 953-961.	1.0	18
72	Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer. <i>Oncotarget</i> , 2018, 9, 32917-32928.	0.8	16

#	ARTICLE	IF	CITATIONS
73	Targeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours. <i>British Journal of Cancer</i> , 2021, 125, 1511-1522.	2.9	16
74	Leucine-rich alpha 2 glycoprotein is a new marker for active disease of tuberculosis. <i>Scientific Reports</i> , 2020, 10, 3384.	1.6	15
75	Interleukin-6 Deficiency Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutation. <i>PLoS ONE</i> , 2016, 11, e0153399.	1.1	15
76	Green tea polyphenol epigallocatechin gallate inhibits cell signaling by inducing SOCS1 gene expression. <i>International Immunology</i> , 2010, 22, 359-366.	1.8	14
77	Suppressor of cytokine signalling β 1 induces significant preclinical antitumor effect in malignant melanoma cells. <i>Experimental Dermatology</i> , 2015, 24, 864-871.	1.4	14
78	Proteomic identification of heterogeneous nuclear ribonucleoprotein K as a novel cold-associated autoantigen in patients with secondary Raynaud's phenomenon. <i>Rheumatology</i> , 2015, 54, 349-358.	0.9	14
79	Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody-Drug Conjugates in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2495-2505.	1.9	14
80	Osteoblast differentiation is impaired in SOCS-1-deficient mice. <i>Journal of Bone and Mineral Metabolism</i> , 2006, 24, 283-290.	1.3	12
81	CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody. <i>Cancer Science</i> , 2015, 106, 1474-1478.	1.7	11
82	Proteomic analysis of autoantigens associated with systemic lupus erythematosus: Anti-aldolase A antibody as a potential marker of lupus nephritis. <i>Proteomics - Clinical Applications</i> , 2007, 1, 185-191.	0.8	10
83	Intratumoral Delivery of an Adenoviral Vector Carrying the <i>SOCS-1</i> Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1941-1950.	1.9	10
84	Anti-Glypican-1 Antibody-Drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1-Positive Cholangiocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1713-1722.	1.9	10
85	SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3K signaling. <i>Gastric Cancer</i> , 2018, 21, 968-976.	2.7	9
86	A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. <i>Neoplasia</i> , 2021, 23, 939-950.	2.3	9
87	The involvement of leucine-rich α 2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model. <i>Modern Rheumatology</i> , 2021, 31, 1120-1128.	0.9	8
88	CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6. <i>Experimental Eye Research</i> , 2015, 140, 53-64.	1.2	7
89	Correlation of increased serum leucine-rich α 2-glycoprotein levels with disease prognosis, progression, and activity of interstitial pneumonia in patients with dermatomyositis: A retrospective study. <i>PLoS ONE</i> , 2020, 15, e0234090.	1.1	7
90	Evaluation of leucine-rich alpha-2 glycoprotein as a biomarker of fetal infection. <i>PLoS ONE</i> , 2020, 15, e0242076.	1.1	7

#	ARTICLE	IF	CITATIONS
91	LSR promotes epithelial ovarian cancer cell survival under energy stress through the LKB1-AMPK pathway. <i>Biochemical and Biophysical Research Communications</i> , 2021, 537, 93-99.	1.0	6
92	The Skin-Liver Axis Modulates the Psoriasiform Phenotype and Involves Leucine-Rich Î±2 Glycoprotein. <i>Journal of Immunology</i> , 2021, 206, 1469-1477.	0.4	6
93	Aberrant expression of glycosylation in juvenile gastrointestinal stromal tumors. <i>Proteomics - Clinical Applications</i> , 2008, 2, 1246-1254.	0.8	5
94	Gene therapy with SOCS1 induces potent preclinical antitumor activities in oral squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2022, 51, 126-133.	1.4	5
95	Increased serum CXCR2 ligand levels in livedo vasculopathy with winter ulcerations: Possible contribution of neutrophil recruitment to lesional skin. <i>Journal of Dermatological Science</i> , 2016, 82, 57-59.	1.0	3
96	Leucine-rich Î±2 glycoprotein is a predictive marker of therapeutic efficacy of the biologics in psoriatic arthritis. <i>Journal of Cutaneous Immunology and Allergy</i> , 2021, 4, 86-88.	0.2	0